Biopsy Devices Market Increasing Prevalence of Chronic Diseases

Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug.

Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases.

They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors marketRheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues.

It causes joints to swell and can result in pain, stiffness, and progressive loss of function.

According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.What Drives the Market?1.

Growing prevalence of targeted therapies2.

[134 pages Report] The aspiration and biopsy needles market is estimated to grow at a CAGR of 7.3% to reach USD 1,272 Million by 2024 from USD 894 Million in 2019.Factors such as the rising prevalence of cancer, initiatives undertaken by government and global health organizations, and the increasing preference for minimally invasive procedures are the major factors driving the growth of the aspiration and biopsy needle market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71036825By site, the breast segment held the largest share of the market in 2019.On the basis of site, the aspiration needles market is segmented into breast, lung, colorectal, prostate, kidney, and bone & bone marrow.

In 2019, the breast cancer segment accounted for the largest share of the market.

The large share of this segment is mainly attributed to the rising prevalence of breast cancer, growing awareness about the disease, and increasing research activity pertaining to breast screening and diagnosis.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=71036825Image-guided procedures accounted for the largest share of the Biopsy Needles Market, by procedureOn the basis of procedure, the Aspiration Needles Market is segmented into image-guided procedures (ultrasound-guided biopsy, stereotactic-guided biopsy, MRI-guided biopsy, and other image-guided procedures) and nonimage-guided procedures.

Image-guided procedures accounted for the largest share of this market in 2018, primarily due to the provision of accuracy provided by it in locating the mass of cells and liquid hence helping it in accuracy for diagnosis.North America accounted for the largest share of the aspiration and biopsy needles market in 2019This report covers the biopsy needles market across four major geographies—North America, Europe, Asia Pacific, and the Rest of the World.

North America commanded the largest share of the fine needle aspiration market in 2019.

Factors such as the increasing prevalence of cancer in the US and Canada and cancer awareness initiatives undertaken by local governments and global health organizations in the North America region are the key factors driving market growth.To speak to our analyst for a discussion on the above findings, click Speak to AnalystKey Market Players:The key players operating in the global Aspiration & Biopsy Needles Market are CONMED Corporation (US), Medtronic Plc (Ireland), Olympus (Japan), Becton, Dickinson and Company (US), Boston Scientific Corporation (US), Cook Group Incorporated (US), Argon Medical Devices, Inc (US), INRAD Inc. (US), Somatex Medical Technologies (Germany), Stryker Corporation (US), Cardinal Health (US), Remington Medical (US), HAKKO CO.,LTD (Japan), and Merit Medical Systems (US)

According to a new market research report Biopsy Devices Market by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74 Billion in 2017, at a CAGR of 6.8% during the forecast period.Browse 180 Market Data Tables and 42 Figures spread through 219 Pages and in-depth TOC on "Biopsy Devices Market"Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=132886515 The Report analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.Factors such as rising prevalence of cancer, increasing preference for minimally invasive surgeries, and initiatives undertaken by governments & global health organizations are the major factors driving the growth of this market.By product, the needle-based biopsy instruments segment accounted for the largest share of the marketOn the basis of product, the needle-based biopsy instruments segment accounted for the largest share of the global biopsy devices market in 2016.

This can be attributed to the preference of needle-based biopsies over open surgical biopsies and increasing preference for minimally invasive surgeries.The lung biopsy segment is expected to highest growth during the forecast periodBased on application, the lung biopsy segment accounted for the largest share of the biopsy devices market.

Additionally, the availability of funding for lung cancer research is contributing to the growth of this market segment.The ultrasound-guided biopsy segment dominated the market in 2016Based on guidance technique, the ultrasound-guided biopsy segment accounted for the largest share of the biopsy devices market.

This quick and simple procedure offers advantages, such as no ionizing radiation exposure, low complication rate, and lower cost as compared to other biopsy techniques.The hospitals segment held the highest CAGR during the forecast periodBased on end user, the hospitals segment is expected to register the highest growth rate during the forecast period.

The strong financial capabilities of hospitals and the presence of trained professionals are the major factors supporting the rising adoption of biopsy devices among hospitals.North America dominated the market in 2016North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe.

The rising prevalence of cancer, government initiatives to spread awareness about cancer, favorable reimbursement scenario for biopsy devices in the U.S., and the presence of key players in the region are the key factors driving the growth of the biopsy devices market in North America.Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515 The major players in the biopsy devices market are C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), and Medtronic plc (Ireland).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.

The Women's Health Diagnostics Market size is forecast to reach $27.18 billion by 2025, growing at a CAGR of 6.83% during the forecast period 2020-2025.

Growing awareness about various health-related disorders among Women’s, rising incidence of various chronic diseases and high prevalence of infectious diseases such as HIV and hepatitis in Women’s is the major factor driving the growth of the market.

High adoption of point-of-care diagnostics and availability of newer and advanced diagnostic systems is set to further enhance the overall market demand for the Women's Health Diagnostics Market during the forecast period 2020-2025.